EUCTR2013-001710-15-FR进行中（未招募）1 期
Phase II study in patient in first line for HER - metastasis breast cancer treated with eribulin and bevacizumab
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patient with a metastasis breast adenocarcinoma, based on histology
- •Positives or negatives hormonal RP and RE receptors, HER 2 negativ, with prersence of at least one mesurable lesion.
- •Biology as follow :
- •Neutrophils > 1,5 x 109/L
- •Platelets > 100 x 109/L
- •Hémoglobin > 9,0 g/dL
- •Bilirubin < 1,5 LSN (Limite Supérieure Normale)
- •Transaminases (ASAT et ALAT et PAL) < 1,5 x upper limit for patient without hepatic metastasis hépatiques et and < 3 if hepatic metastasis
- •Age > 18 ans.
- •Availabilty to follows the protocole's rules.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •Previous chemotherapy
- •Previoulsy treated with eribulin or bevacizumab
- •brain metastasis
- •previous cancer ( exept cancer treated with no relase within the 5 years before the start of the study)
- •Participation in another study within the previous 30 days
研究者
相似试验
招募中
2 期
Patient reported preference for subcutaneous MK-3475-A over intravenous pembrolizumab formulation in multiple tumor typesEarly-stage or advanced/metastatic solid tumorsJPRN-jRCT2051230147Koh Yasuhiro5
招募中
1 期
Patient Preference Study of SC Pembrolizumab versus IV Pembrolizumab with hyaluronidase (MK-3475A) in multiple cancer typesCTIS2023-506017-22-00Merck Sharp & Dohme LLC144
招募中
2 期
Comparative study of conventional and new treatments for patients with intrauterine infectionsPreterm laborD007752JPRN-jRCTs071210114Miyamoto Shingo24
进行中（未招募）
不适用
Estudio clínico de fase IIa, del tratamiento con heparina topica en pacientes con sindrome eritrodisestesico palmo-plantar asociado a capecitabinasíndrome eritrodisestésico palmo-plantarMedDRA version: 9Level: LLTClassification code 10033553Term: Palmar-plantar erythrodysaesthesia syndromeEUCTR2009-018171-13-ESONCOSUR
进行中（未招募）
1 期
A first-in-human study of UX053 in Patients with Glycogen Storage Disease type III (GSD III)Glycogen Storage Disease Type III (GSD III)MedDRA version: 20.1Level: PTClassification code 10053250Term: Glycogen storage disease type IIISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-000903-19-ITTRAGENYX PHARMACEUTICAL INC.30